Holen Sie sich die Stockscreener-App
9.5794
0.25%
0.0906
Schlusskurs vom Vortag:
$9.67
Offen:
$9.49
24-Stunden-Volumen:
15,817
Relative Volume:
0.39
Marktkapitalisierung:
$132.47M
Einnahmen:
$49.98M
Nettoeinkommen (Verlust:
$-9.64M
KGV:
-13.49
EPS:
-0.71
Netto-Cashflow:
$-4.86M
1W Leistung:
+0.36%
1M Leistung:
+53.15%
6M Leistung:
+93.50%
1J Leistung:
+44.48%
1-Tages-Spanne:
$9.4018
$9.6944
1-Wochen-Bereich:
$8.93
$9.9199
52-Wochen-Spanne:
$3.6001
$10.90
Champions Oncology Inc Stock (CSBR) Company Profile
Firmenname
Champions Oncology Inc
Sektor
Branche
Telefon
410-369-0365
Adresse
855 N. WOLFE STREET, BALTIMORE, NJ
Vergleichen Sie CSBR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
9.5794 | 132.47M | 49.98M | -9.64M | -4.86M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.20 | 106.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.92 | 75.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
659.80 | 39.80B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.62 | 31.02B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.95 | 26.95B | 3.30B | -501.07M | 1.03B | -2.1146 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-12 | Hochstufung | Craig Hallum | Hold → Buy |
| 2019-11-18 | Eingeleitet | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Aktie (CSBR) Neueste Nachrichten
Addressing Climate Change by Changing Our Food Systems - NTB Kommunikasjon
Champions Oncology integrates Cytek Aurora flow cytometers - Yahoo Finance
IXOPAY & Riskified Announce Partnership to Boost Fraud Prevention and Enhance Enterprise Payment Orchestration - Via Ritzau
Champions Oncology bolsters bioanalytical services By Investing.com - Investing.com Canada
Champions Oncology bolsters bioanalytical services - Investing.com India
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership - AccessWire
Champions Oncology Boosts Bioanalytical Services with Cytek Aurora Tech and Key Executive Hire - StockTitan
Champions Oncology, Inc.'s (NASDAQ:CSBR) market cap up US$26m last week, benefiting both private equity firms who own 30% as well as insiders - Simply Wall St
Linacre Investments Limited Delivers Record-Breaking Returns for 2024 - Via Ritzau
Patient Derived Xenograft Model Market Future Business - openPR
CSBR stock hits 52-week high at $9.94 amid growth By Investing.com - Investing.com Australia
CSBR stock hits 52-week high at $9.94 amid growth - Investing.com
Ch Champions Oncology, Inc. Enhances Clinical Bioanalytical Services Portfolio with New Technology - Marketscreener.com
Learn to Evaluate (CSBR) using the Charts - Stock Traders Daily
Champions Oncology Reports Quarterly Revenue of $6.7 Million - AccessWire
CSBR stock touches 52-week high at $8.92 amid robust growth - Investing.com Nigeria
CSBR stock touches 52-week high at $8.92 amid robust growth By Investing.com - Investing.com South Africa
Champions Oncology: Right Point To Own In The Cycle Thanks To Operating Efficiencies - Seeking Alpha
The Bilingual Book Company Launches New, Innovative Bilingual Audiobook App - NTB Kommunikasjon
Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence - Via Ritzau
Private equity firms invested in Champions Oncology, Inc. (NASDAQ:CSBR) up 19% last week, insiders too were rewarded - Yahoo Finance
CSBR stock hits 52-week high at $7.15 amid robust growth - Investing.com Australia
Champions Oncology Second Quarter 2025 Earnings: EPS: US$0.054 (vs US$0.15 loss in 2Q 2024) - Simply Wall St
Champions Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2025 Earnings Call Transcript - Insider Monkey
Champions Oncology Inc. (CSBR) reports earnings - Quartz
Loar Holdings Inc. Announces the Grant of Inducement Awards - Via Ritzau
Earnings call transcript: Champions Oncology Q2 2024 beats forecasts, stock surges - Investing.com
Champions Oncology Posts Strong Quarterly Revenue Growth - TipRanks
Champions Oncology earnings beat by $0.08, revenue topped estimates - Investing.com Canada
Stocks to Watch : Adobe, Champions Oncology, DBV Technologies - Marketscreener.com
Stocks to Watch: Adobe, Champions Oncology, DBV Technologies - MarketWatch
Champions Oncology Shares Rise on Higher 2Q Profit, Revenue - MarketWatch
Champions Oncology Q2 Earnings Surge: Revenue Soars 17% as Operational Efficiency Drives Profitability - StockTitan
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million - AccessWire
Adobe, Macy's, Nordson, and more set to report earnings Wednesday By Investing.com - Investing.com Nigeria
3 US Dividend Stocks To Consider With Up To 4.6% Yield - Simply Wall St
Is Koppers Holdings (NYSE:KOP) Using Too Much Debt? - Simply Wall St
Sentiment Still Eluding Champions Oncology, Inc. (NASDAQ:CSBR) - Simply Wall St
Patient Derived Xenograft Model Market Is Booming Worldwide - openPR
Champions Oncology Sets Date for Q2 2024 Earnings Release & Conference Call - StockTitan
Polaris Renewable Energy Successfully Settles USD 175 Million Bond Issue - TT Nyhetsbyrån
[Latest] Patient Derived Xenograft (Pdx) Models Market : An Overview - openPR
Patient Derived Xenograft (PDX) Models Market Company - openPR
Polaris Renewable Energy Successfully Places USD 175 Million Bond Issue - NTB Kommunikasjon
Champions Oncology (NASDAQ:CSBR) shareholders have endured a 61% loss from investing in the stock three years ago - Yahoo Finance
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth - Simply Wall St
Shangri-La Mactan champions Breast Cancer Awareness with 'Pink Path to Hope' Fun Run and Wellness Forum - SunStar Philippines
CancerX Launches Expanded Accelerator Program for 2025, Partnering With KidsX to Transform Cancer Care Innovation - 01Net
Custom Assay Development Service Market Size, Share, Growth Forecast and Trends Analysis (2024-2032) - Economica
Opti Digital Breaks Down the Biggest AdTech Trends in 2025 - Via Ritzau
Finanzdaten der Champions Oncology Inc-Aktie (CSBR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.62%
5.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):